CAVA Group Inc vs IDEXX Laboratories, Inc. — how do they compare? CAVA Group Inc trades at $68.47 (market cap $7.08B), while IDEXX Laboratories, Inc. trades at $571.28 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.5× CAVA Group Inc's market cap, and CAVA Group Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| CAVA | IDXX | |
|---|---|---|
Market Cap | $7.08B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $97.39 | $766.68 |
52-Week Low | $43.59 | $526.44 |
Enterprise Value | $7.23B | $47.12B |
Signals from Pluang's Aura AI — not financial advice
CAVA trades at $69.68, up 13.15% with strong Q2 2026 earnings beats and 31.3% revenue growth. Technicals are bearish with support at $58, while fundamentals show high P/E of 108.59 but robust same-store sales. News highlights include menu innovation driving traffic and earnings outperformance.
Outlook is positive with a $89.75 consensus price target and 76% buy ratings, though valuation and net cash outflows pose risks. Growth momentum from new restaurants and consumer demand supports upside, but margin pressure and competition require monitoring.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Trailing returns across standard periods
Latest headlines on both assets
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →